GE HealthCare Adds AI Guidance to Cardiac Ultrasound Assessments with Vscan Air SL
The addition of Caption AI to the handheld ultrasound device Vscan Air SL may facilitate optimal imaging for point-of-care cardiac evaluation.
In order to expand access to cardiac assessments via point-of-care ultrasound, GE HealthCare has added Caption AI capability to its Vscan Air SL handheld ultrasound device.
Through Caption AI’s use of artificial intelligence (AI)-enabled guidance to assist with ultrasound probe placement and imaging, GE HealthCare said the software can promote greater confidence in the use of Vscan Air SL to perform timely cardiac evaluation, even for those clinicians who lack ultrasound expertise.
" ... Innovations like the Vscan Air SL with Caption AI are hugely transformative in cardiac care, supporting rapid and confident assessments at the point of care," said cardiologist Jordan B. Strom, M.D., MSc, an assistant professor of medicine at Harvard Medical School and director of echocardiographic research at the Beth Israel Deaconess Medical Center in Boston. (Image courtesy of GE HealthCare.)
In addition to a sector-phased array transducer, the Vscan Air SL also has an AutoEF feature, which provides automated calculation of left ventricular ejection fraction (LVEF), according to GE HealthCare.
The company suggested that the expanded capabilities of Vscan Air SL with Caption AI, which will be showcased at the American College of Cardiology (ACC) Annual Scientific Session and Expo later this week in Atlanta, could have an impact for earlier detection of heart disease in patients at resource-challenged facilities.
"With the increase of cardiovascular disease and shortage of sonographers around the globe, innovations like the Vscan Air SL with Caption AI are hugely transformative in cardiac care, supporting rapid and confident assessments at the point of care," said cardiologist Jordan B. Strom, M.D., MSc, an assistant professor of medicine at Harvard Medical School and director of echocardiographic research at the Beth Israel Deaconess Medical Center in Boston.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
